GE HEALTHCARE TECHNOLOGIES INC. vs STRYKER CORP, two Medical Devices stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Both prices bet on hospital capital spending, but at different confidence levels: Stryker at 38.5 times earnings is priced as the sector's execution machine, GE HealthCare at 15.8 as an industrial that happens to sell MRI machines. The economics justify some gap, Stryker's 15.6% operating margin against 10%, its 63.3% gross against 38.5%, but the multiples more than double it. GEHC's spinoff-era balance sheet, 0.95 turns and negative free cash this year, earns some of the discount honestly; Stryker converts 3.6% of its price to cash and pays a dividend. Twenty-three turns of spread for six points of operating margin: the market is pricing culture and track record, not just arithmetic.
Comparison updated 2026-07-10.
| Metric | GEHC | SYK |
|---|---|---|
| Price | $65.69 | $332.30 |
| Market cap | $30.0B | $128.4B |
| Sector | Medical Devices | Medical Devices |
| Stage | Mature | Mature |
| Implied growth (priced in) | +6.5% | +23.7% |
| P/E | 15.8 | 38.5 |
| P/B | 2.81 | 5.59 |
| P/S | 1.43 | 5.08 |
| EV/EBITDA | 13.9 | 21.3 |
| Revenue growth | +5.9% | +8.8% |
| Gross margin | 38.5% | 63.3% |
| Operating margin | 10.0% | 15.6% |
| Net margin | 9.1% | 13.2% |
| Return on equity | 17.9% | 14.5% |
| Return on assets | 5.1% | 7.2% |
| Return on invested capital | 10.4% | 11.6% |
| FCF yield | -0.4% | 3.6% |
| Dividend yield | 0.2% | 0.5% |
| Debt / equity | 0.95 | 0.64 |
| Current ratio | 1.22 | 2.11 |
| Altman Z (solvency) | 1.57 | 4.73 |
| Piotroski F (quality) | 4 / 9 | 5 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.